ClinicalTrials.gg
CompletedNCT05169580Updated Feb 12, 2026

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir

A Phase 1 interventional study of Pociredir oral capsule(s) in Sickle Cell Disease and Sickle Cell Anemia, sponsored by Fulcrum Therapeutics. Completed at 18 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Fulcrum Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
218th of 559
45 · median 31
Started
2021
with 40 others
Phase 1
98 of 733
13 open now
Registered
571st of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 218th largest by enrollment of the 559 interventional ones that give a count, is one of 41 that started in 2021, is one of 98 in phase 1, and was the 571st registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Pociredir in participants with sickle cell disease.

Read the detailed description

This is a Phase 1 multicenter, international, open-label study evaluating the safety, tolerability, pharmacokinetics (PK), fetal hemoglobin (HbF) induction and biological activity of Pociredir in participants 18-65 years of age, inclusive, with SCD.

Participants will receive 12 weeks of dosing with 4 weeks of follow-up. Approximately 10 participants will be enrolled in each cohort. A maximum of 3 participants with SCD HbSC+ genotype may be enrolled in each cohort.

Cohort 1 will receive 6 milligrams (mg) of Pociredir by mouth once daily. Doses for subsequent cohorts will be determined following review by the Data Monitoring Committee [DMC]. A total of seven cohorts may be included. Cohort 2 will be dosed at 2 mg once daily by mouth, and cohort 3 will be dosed at 12 mg once daily by mouth. The Sponsor will reinitiate enrolment in the 3rd cohort (12 mg cohort) with the updated inclusion and exclusion criteria. Based on review of available safety and biomarker data and with the recommendation of the DMC, a subsequent 4th cohort of 20 mg and potentially a 5th cohort of 30 mg may be initiated. Additional cohorts using alternative dosing schedules may be considered based on available data.

The primary endpoints of the study are to evaluate the safety and tolerability of Pociredir as measured by the frequency of adverse events and to evaluate single and multiple-dose pharmacokinetics of Pociredir in participants with sickle cell disease. Secondary endpoints include evaluating the effect of Pociredir on fetal hemoglobin induction in peripheral blood and evaluating the effects of Pociredir on hemolysis in participants with sickle cell disease.

03

Conditions studied

  • Sickle Cell Disease
  • Sickle Cell Anemia

Browse trials for

Keywords

  • Sickle Cell Disease
  • Sickle Cell Anemia
  • Pharmacokinetics
  • Pharmacodynamics
  • Pociredir
  • Open label
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant is 18 to 65 years of age, inclusive at the time is obtained.
  • Documented SCD at the time of screening (S/S, S/β0, S/β+, and S/C only) as confirmed through review of medical records or HPLC.
  • Participants who meet at least one the following criteria:

    1. ≥4 to 10 episodes of SCD pain crisis over 12 months, or ≥2 to 5 over 6 months prior to screening
    2. ≥2 episodes of SCD pain crisis plus at least one of the following over previous 12 months: i) Acute chest syndrome (ACS) ii. Hepatic or splenic sequestration iii. Priapism
    3. ≥2 of the following events over the previous 12 months:i. ACS ii. Hepatic or splenic sequestration iii. Priapism
    4. Tricuspid regurgitant jet velocity (TRV) ≥ 3.0 meter/second(m/s) OR TRV ≥ 2.5 m/s + N-terminal pro b-type natriuretic peptide (NT-proBNP) plasma level ≥ 160 picogram per milliliter; OR documented ongoing pulmonary hypertension diagnosed from previous echocardiogram or right-sided heart catheterization with mean pulmonary artery pressure > 25 millimeter of mercury;
    5. SCD-related chronic kidney disease (CKD)
    6. Meet medical criteria to receive (e.g., post-cerebrovascular accident) but are for chronic transfusions (e.g., alloimmunization, transfusion reactions)
  • Previous experience with Hydroxyurea (HU) but have shown to be unresponsive and/or intolerant or ineligible AND
  • Previous experience with a stable dose of voxelotor, crizanlizumab, and/ or L-glutamine but have shown to be unresponsive and/or intolerant or ineligible
  • Per Investigator's recommendation, participants may continue crizanlizumab and/or L-glutamine but must be on a stable dose for at least 6 months
  • HbF ≤ 20% of total
  • Total Hb ≥ 5.5 g/dL and ≤ 12 g/dl (males) or ≤ 10.6 g/dl (females) at screening.
  • Participant must meet both of the following laboratory values at screening:

    1. ≥ 1.5 × 10\^9 per liter (/l)
    2. ≥ 80 × 10\^9/l
    3. Absolute reticulocyte count at screening ≥ 100 x 10\^9/l.

Key Exclusion Criteria:

  • Sickle cell complication requiring care from a medical provider in hospital or emergency care setting in the 14 days prior to starting study drug.
  • History of bone marrow transplant or human stem cell transplant or gene therapies.
    • Participants with a history of severe renal disease defined as estimated \< 30 mL/min/1.73m\^2. Participants on dialysis of any kind are excluded.
  • Participants receiving regularly scheduled transfusions or therapeutic phlebotomies, or any participant who has been transfused within 60 days prior to initiating study drug.
  • Participant with active , or history of cancer (except for squamous cell skin cancer, basal cell skin cancer, and stage 0 cervical carcinoma in situ, with no recurrence for the last 5 years), or has an immediate family member with known or suspected familial cancer syndrome. Known presence of a chromosomal abnormality or genetic mutation that may put the participant at an increased risk of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
  • Participant currently on HU, or have received HU, within 60 days prior to initiating study drug.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Pociredir oral capsule(s) in Sickle Cell participants

    Cohort 1 will receive 6 mg of Pociredir by mouth once daily. Cohort 2 will be dosed at 2 mg once daily by mouth, and cohort 3 will be dosed at 12 mg once daily by mouth. The Sponsor will reinitiate enrolment in the 3rd cohort (12 mg cohort) with the updated inclusion and exclusion criteria. Based on review of available safety and biomarker data and with the recommendation of the DMC, a subsequent 4th cohort of 20 mg and potentially a 5th cohort of 30 mg may be initiated. A total of seven cohorts may be included. Following the first cohort, doses for all subsequent cohorts will be determined following DMC review of the safety and pharmacokinetic data observed in participants from the prior and ongoing cohorts. Alternate dosing schedules may be evaluated in some of the cohorts.

    Drug: Pociredir oral capsule(s)

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment-Emergent Adverse Events

    To evaluate the safety and tolerability of Pociredir in adult participants with sickle cell disease based on the frequency of adverse events (AEs) and changes in clinically significant laboratory test results, vital signs and electrocardiograms (ECGs) parameters.

    Time frame: Up to approximately 16 weeks of monitoring

  2. Plasma Concentrations of Pociredir

    Blood samples will be collected to measure the plasma concentration of Pociredir at specified timepoints.

    Time frame: Days 1, 14, 28, 42, 56, 70, 84 and 91

Secondary outcomes

  1. Change from Baseline in percentage fetal hemoglobin (%HbF) biomarkers in peripheral blood

    The percentage of HbF will be measured in peripheral whole blood.

    Time frame: Baseline and at Days 1, 14, 28, 42, 56, 70, 84, 91, and 112

  2. Change from Baseline in % Reticulocytes

    The percentage of reticulocytes will be measured in peripheral whole blood.

    Time frame: Baseline and at Days 1, 14, 28, 42, 56, 70, 84, 91, and 112

  3. Change from Baseline in Absolute Reticulocyte Count

    The absolute reticulocyte count will be measured in peripheral whole blood.

    Time frame: Baseline and at Days 1, 14, 28, 42, 56, 70, 84, 91, and 112

  4. Change from Baseline in Red cell distribution width

    Blood samples will be collected for the analysis of hematology parameter: red cell distribution width

    Time frame: Baseline and at Days 1, 14, 28, 42, 56, 70, 84 and 91

  5. Change from Baseline in unconjugated bilirubin

    Blood samples will be collected for the analysis of clinical chemistry parameter: unconjugated bilirubin

    Time frame: Baseline and at Days 1, 14, 28, 42, 56, 70, 84 and 91

07

Study locations

18 sites
  • University of Arkansas for Medical Sciences (UAMS)
    Little Rock, Arkansas 72205, United States
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Sonar Research Center
    Atlanta, Georgia 30315, United States
  • University of Illinois Chicago
    Chicago, Illinois 60612, United States
  • Our Lady of the Lake Hospital
    Baton Rouge, Louisiana 70808, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Queens Hospital Cancer Center
    Jamaica, New York 11432, United States
  • Jacobi Medical Center
    The Bronx, New York 10461, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Eastern Carolina University
    Greenville, North Carolina 27834, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • University of Texas Houston
    Houston, Texas 77030, United States
  • Inova Schar Cancer Institute
    Fairfax, Virginia 22031, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • National Hospital, Abuja
    Abuja, 900247, Nigeria
  • University of Ibadan
    Ibadan, 200212, Nigeria
  • Barau Dikko Teaching Hospital
    Kaduna, 800125, Nigeria
  • Charlotte Maxeke Johannesburg Academic Hospital
    Johannesburg, 2193, South Africa
08

References and documents

Publications

  • Ngo DA, Aygun B, Akinsheye I, Hankins JS, Bhan I, Luo HY, Steinberg MH, Chui DH. Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin. Br J Haematol. 2012 Jan;156(2):259-64. doi: 10.1111/j.1365-2141.2011.08916.x. Epub 2011 Oct 24. PubMed 22017641 ↗
  • Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017 Apr 20;376(16):1561-1573. doi: 10.1056/NEJMra1510865. No abstract available. PubMed 28423290 ↗
  • Sankaran VG, Orkin SH. The switch from fetal to adult hemoglobin. Cold Spring Harb Perspect Med. 2013 Jan 1;3(1):a011643. doi: 10.1101/cshperspect.a011643. PubMed 23209159 ↗
  • Saraf SL, Molokie RE, Nouraie M, Sable CA, Luchtman-Jones L, Ensing GJ, Campbell AD, Rana SR, Niu XM, Machado RF, Gladwin MT, Gordeuk VR. Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatr Respir Rev. 2014 Mar;15(1):4-12. doi: 10.1016/j.prrv.2013.11.003. Epub 2013 Nov 15. PubMed 24361300 ↗
  • Steinberg MH, Chui DH, Dover GJ, Sebastiani P, Alsultan A. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood. 2014 Jan 23;123(4):481-5. doi: 10.1182/blood-2013-09-528067. Epub 2013 Nov 12. PubMed 24222332 ↗
  • Abbasi M, Srivastava A, Saraf SL. Management of Kidney Disease with Sickle Cell Disease. J Am Soc Nephrol. 2025 Oct 1;36(10):2041-2054. doi: 10.1681/ASN.0000000804. Epub 2025 Jun 26. PubMed 40569673 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jan 2026, 49 months.

Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 49 months is above that.

Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2021
First posted
Dec 27, 2021
StartActual
Dec 13, 2021
Primary completionActual
Jan 20, 2026
CompletionActual
Jan 20, 2026
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05169580
Lead sponsor
Fulcrum Therapeutics
Responsible party
Sponsor
First posted
Dec 27, 2021
Start date
Dec 13, 2021
Primary completion
Jan 20, 2026
Completion
Jan 20, 2026
Last update
Feb 12, 2026

Study contacts

Adeyemi Adenola, MD
study director · Fulcrum Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pociredir

Start the discussion